Latest Ratios: P/E Ratio 74.4x · EV/EBITDA 89.2x · ROE 27.0%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $522M | $1.3B | — | — | — | — |
| Enterprise Value | $515M | $1.3B | — | — | — | — |
| P/E Ratio → | 74.38 | 187.94 | — | — | — | — |
| P/S Ratio | 60.40 | 152.63 | — | — | — | — |
| P/B Ratio | 17.32 | 43.77 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 151.74 | — | — | — | — |
| EV / EBITDA | 89.21 | 227.48 | — | — | — | — |
| EV / EBIT | 89.21 | 227.48 | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 87.2% | 87.2% | 71.9% | 50.1% | 53.4% | 57.4% |
| Operating Margin | 66.7% | 66.7% | 24.4% | 29.2% | 43.3% | 55.5% |
| Net Profit Margin | 74.1% | 74.1% | 29.0% | 33.6% | 42.5% | 57.3% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | 27.0% | 27.0% | 14.8% | 16.5% | 132.7% | 100.0% |
| ROA | 26.0% | 26.0% | 13.7% | 15.1% | 106.1% | 51.6% |
| ROIC | 31.1% | 31.1% | 28.3% | 27.8% | 402.5% | — |
| ROCE | 24.4% | 24.4% | 12.5% | 14.3% | 135.2% | 96.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.26 | -0.68 | -0.65 | -0.57 | -1.65 |
| Net Debt / EBITDA | -1.35 | -1.35 | -4.58 | -4.91 | -0.70 | -1.65 |
| Debt / FCF | — | — | -5.65 | -10.78 | -1.60 | -1.00 |
| Interest Coverage | — | — | — | — | 1252.55 | — |
Net cash position: cash ($8M) exceeds total debt ($0)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 344.31 | 344.31 | 10.71 | 15.86 | 9.88 | 2.07 |
| Quick Ratio | 344.31 | 344.31 | 10.71 | 15.86 | 9.63 | 2.07 |
| Cash Ratio | 135.49 | 135.49 | 6.80 | 9.76 | 6.14 | 1.76 |
| Asset Turnover | — | 0.29 | 0.43 | 0.42 | 1.69 | 0.90 |
| Inventory Turnover | — | — | — | — | 31.03 | — |
| Days Sales Outstanding | — | 154.37 | 47.48 | 102.50 | 0.06 | 59.14 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | 1.3% | 0.5% | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $44M | $42M | $188M | $144M | $100M |
Revenue volatility and scale
Based on current market data, NNNN trades at a P/S ratio of 68.81, which appears disconnected from the company's recent revenue contraction and suggests that investors are pricing in a recovery that is not yet supported by the underlying financial performance or consistent growth trajectories.
The elevated P/E of 95.62 and EV/EBITDA of 101.97 indicate that the market is assigning a significant growth premium to the firm despite the recent shift to negative net margins. This valuation appears to rely on the assumption of a rapid return to peak profitability, which may be overly optimistic given the current instability in the diagnostic testing market.
According to recent financial filings, NNNN's ROIC plummeted to -19.2% in 2024Q4, a sharp reversal from the 44.1% peak observed in 2024Q2, indicating that the company is currently struggling to generate meaningful returns on its invested capital as operational costs outpace revenue generation.
The volatility in ROIC suggests that the company's asset-light model is highly sensitive to top-line fluctuations, as the lack of scale prevents the absorption of fixed costs during downturns. Investors should monitor whether this decay in capital efficiency is a structural issue or a temporary byproduct of the current transition in the product mix.
As reported in financial statements, NNNN's DSO reached 103 days in 2024Q4, a significant increase from 22 days in 2023Q4, which suggests that the company is facing increasing difficulty in collecting receivables and managing its cash conversion cycle effectively in the current competitive environment.
The wide swings in DSO and DPO indicate that the company's working capital management is not yet optimized for a stable, recurring revenue model. This inefficiency may be masking underlying liquidity pressures that are not immediately apparent given the company's strong cash position.
Based on NNNN's reported figures, the company maintains a current ratio of 10.71 as of 2024Q4, providing a substantial buffer against short-term liabilities, though this high level of liquidity may also indicate an inefficient allocation of capital that is not being deployed for growth.
While the fortress balance sheet protects the firm from immediate solvency risks, the lack of debt and high cash balance suggest that management may be struggling to identify high-return reinvestment opportunities. This liquidity position warrants further investigation into whether the company is prioritizing capital preservation over necessary R&D or market expansion.
Investors frequently misapply the net margin metric to NNNN, as the reported 74.06% peak profitability is often skewed by non-operating gains and does not reflect the underlying volatility of the core diagnostic business model, which is better analyzed through operating cash flow and gross margin trends.
Relying on net margins for a company in this stage of development obscures the reality of its operational cost structure and the sustainability of its earnings. Analysts should instead focus on gross margin stability and free cash flow conversion to better understand the true earning power of the company's diagnostic platform.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NNNN stock.
Anbio Biotechnology Class A Ordinary Shares's current P/E ratio is 74.4x. The historical average is 187.9x.
Anbio Biotechnology Class A Ordinary Shares's current EV/EBITDA is 89.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA.
Anbio Biotechnology Class A Ordinary Shares's return on equity (ROE) is 27.0%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 58.2%.
Based on historical data, Anbio Biotechnology Class A Ordinary Shares is trading at a P/E of 74.4x. Compare with industry peers and growth rates for a complete picture.
Anbio Biotechnology Class A Ordinary Shares has 87.2% gross margin and 66.7% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.